As an award winning innovative diagnostic company, ProAxsis has developed unique patented technology and a growing CE marked product portfolio, alongside expert services provided to both Commercial and Healthcare organizations. With Respiratory at the heart of ProAxsis portfolio, it has teamed up with AstraZeneca and an inlicensing agreement to support the development of a COVID Antibody test. Biomarkers remain a priority focus as does Respiratory care whilst we have innovatively moved forward with Bone Health also. Stay tuned for further developments.